- Harrow reported that 15 scientific abstracts across its ophthalmic portfolio were presented at the AAOpt and AAO 2026 meetings, covering conditions from dry eye disease to post operative inflammation with data ranging from Phase 3 trials to real world evidence.
- The breadth of clinical and long term safety data on products such as VEVYE, VERKAZIA, FLAREX, and BYQLOVI highlights the extent of Harrow's investment in evidence generation to support prescribing confidence and potential indication breadth across multiple ocular disorders.
- This article examines how Harrow's investment narrative is influenced by this wave of Phase 3 and long term ophthalmic data disclosure.
Scan beyond Harrow to compare this kind of clinical momentum with other eyecare and specialty pharma names screened as 32 healthcare AI stocks.
Harrow Investment Narrative Recap
For Harrow, the simple thesis is that an ophthalmic focused platform can turn a broad portfolio into sustained prescription demand while moving from losses toward profitability. To stay comfortable as a shareholder, you need to believe that branded products like VEVYE and BYQLOVI can scale within the infrastructure Harrow has already built. The fresh wave of clinical data is helpful for reinforcing that story but does not, by itself, change the near term picture.
The main short term catalyst still sits in execution on branded drug uptake and access programs. In that context, prescription trends and margins will matter more than conference visibility. The biggest near term risk stays the same. Concentration in a handful of key ophthalmic products, combined with pricing and reimbursement pressure, could limit how much of the forecasted revenue and earnings trajectory actually shows up.
The most relevant update is Harrow’s disclosure of 15 abstracts at AAOpt and AAO in late 2026, including Phase 3 and long term safety data for VEVYE, VERKAZIA, FLAREX, and BYQLOVI. That level of breadth gives prescribers more information across dry eye disease, VKC, ocular inflammation, chronic blepharitis, and post operative pain.
For you, the link to catalysts is practical. Stronger evidence and longer term safety readouts can support label usage and confidence in repeat prescribing. That, in turn, connects to the revenue growth analysts are modeling at 27.3% a year. The risk side is that if real world experience or future analyses do not line up with these results, Harrow’s dependence on a few core brands becomes more exposed.
Harrow's narrative projects US$784.8 million revenue and US$246.0 million earnings by 2029. This assumes 42.9% yearly revenue growth and an earnings increase of about US$261.0 million from a loss of US$15.0 million today.
Uncover why Harrow's fair value indicates a 124% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
You might see these 15 Harrow abstracts as a clear catalyst for stronger branded uptake. The lowest analysts focus on the opposite risk, slower adoption for new products despite conference buzz. Before this news, they were only penciling in US$773.9 million revenue and US$148.7 million earnings by 2029. That gap in expectations shows how far opinions can stretch, so consider using this data drop as an opportunity to review several viewpoints rather than looking only at the consensus.
Explore 2 other Harrow fair value estimates, including one that suggests it could be worth just $45.00!
The Verdict Is Yours
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Harrow research is our analysis highlighting 3 key rewards that could impact your investment decision.
- See our latest analysis for Harrow. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Harrow's overall financial health at a glance.
Looking for more Harrow sized investment ideas?
If the Harrow story has sharpened your thinking about risk, reward, and clinical momentum, you can use that same framework to scan a wider field of opportunities with the Simply Wall St Screener.
- For investors hunting for mispriced quality, you might start with companies that pair strong fundamentals with attractive valuations through the 27 high quality undervalued stocks.
- If capital preservation matters most to you, you might focus on businesses that score well on resilience and financial risk using the 31 resilient stocks with low risk scores.
- When you want growth potential without stretching balance sheets, you might look at companies with strong financial footing and healthy metrics through the list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com